ERBB2 and breast carcinoma: In summary, ES2B-C001 displayed a remarkable preclinical activity in vivo against mouse mammary carcinomas expressing human HER-2, inducing strong specific antibody responses that inhibited human HER-2-positive breast cancer cells in vitro.